Evidence map›Paper›PMID 40683955›Full record

ArticleScientific reports2025

ROC analysis determines optimal cutoff and doubtable interval of the Bath ankylosing spondylitis metrology index in a multicenter case control study.

Genggeng Guo, Juanjuan He, Jianwen Liu, Xiaoye Yan, Meng Zhou, Chenmin Wu, Diantian Lin, Zhihan Chen, Qing Yan, Fei Gao and 3 more

Abstract readMulticenter Study
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Genggeng Guo *Department of Rheumatology, Affiliated Shengli Hospital of Fuzhou University, Fuzhou, 350001, Fujian Province, People's Republic of China.
Juanjuan HeDepartment of Rheumatology, Affiliated Shengli Hospital of Fuzhou University, Fuzhou, 350001, Fujian Province, People's Republic of China.
Jianwen LiuDepartment of Rheumatology, Affiliated Shengli Hospital of Fuzhou University, Fuzhou, 350001, Fujian Province, People's Republic of China.
Xiaoye YanDepartment of Rheumatology, Affiliated Shengli Hospital of Fuzhou University, Fuzhou, 350001, Fujian Province, People's Republic of China.
Meng ZhouDepartment of Rheumatology, Affiliated Shengli Hospital of Fuzhou University, Fuzhou, 350001, Fujian Province, People's Republic of China.
Chenmin WuDepartment of Rheumatology, Affiliated Shengli Hospital of Fuzhou University, Fuzhou, 350001, Fujian Province, People's Republic of China.
Diantian LinDepartment of Rheumatology, Affiliated Shengli Hospital of Fuzhou University, Fuzhou, 350001, Fujian Province, People's Republic of China.
Zhihan ChenDepartment of Rheumatology, Affiliated Shengli Hospital of Fuzhou University, Fuzhou, 350001, Fujian Province, People's Republic of China.
Qing YanDepartment of Rheumatology, Affiliated Shengli Hospital of Fuzhou University, Fuzhou, 350001, Fujian Province, People's Republic of China.
Fei GaoDepartment of Rheumatology, Affiliated Shengli Hospital of Fuzhou University, Fuzhou, 350001, Fujian Province, People's Republic of China.
Zugang XieDepartment of Rheumatology, People's Hospital of Longyan, Longyan, 364000, Fujian Province, People's Republic of China.
Feng HuangDepartment of Rheumatology and Immunology, The First Medical Center, Chinese PLA General Hospital, Beijing, 100853, People's Republic of China. fhuang@301hospital.com.cn.
Shengli Zhang *Department of Rheumatology, Affiliated Shengli Hospital of Fuzhou University, Fuzhou, 350001, Fujian Province, People's Republic of China. slzhang301@163.com.

Funding

Fujian Province science and technology innovation joint fund 2023Y9602Longyan Science and Technology Innovation Joint Fund Health Project 2024LYF17018
6 · The paper itself

Abstract

In clinical practice, the Bath Ankylosing Spondylitis Metrology Index (BASMI) score of healthy individuals is more than zero. However, the lower limit of the BASMI score range for patients with ankylosing spondylitis (AS) is 0, which is inconsistent with that observed in actual clinical settings. Based on findings from a multicenter case-control study, the receiver operating characteristic (ROC) curve was used to determine the optimal cutoff value and doubtable value interval of BASMI, thereby providing a reference to facilitate the evaluation of patients with AS.Patients with AS and healthy controls were recruited, and their demographic characteristics were examined. Spinal mobility was assessed by our standardized and trained measurement team. We used the SPSS26.0 statistical software to categorize the pertinent BASMI scores of the patients and healthy controls by age and sex. We subsequently prepared the BASMI ROC curve, calculated the Youden index, and determined the optimal cutoff value and doubtable value interval. In the present study, 246 patients with AS (patient group) and 246 healthy controls (control group) were recruited. Only three (0.9%) and four (1.18%) individuals in the control and patient groups had a BASMI score of 0, respectively. The optimal cutoff value of BASMI in the general population was 1.5 points, the doubtable value interval was 0.7-2.1 points, and the area under the ROC curve was 0.867 (95% confidence interval, 0.835-0.899; P < 0.001). The optimal cutoff value of BASMI was determined as part of a preliminary analysis.A BASMI score > 1.5 may signal spinal mobility limitations; however, its clinical relevance requires validation against functional and structural progression endpoints.Furthermore, when the BASMI score of an individual range from 0.7 to 2.1, it is crucial to determine whether the individual has AS.

Indexed as

Severity of Illness IndexSpondylitis, AnkylosingAdultCase-Control StudiesFemaleHumansMaleMiddle AgedROC CurveAnkylosing spondylitisBASMIDoubtable value intervalOptimal cutoff valueROC curve

Identifiers

PMID40683955
PMCPMC12276213

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.